NEXGEL stock fell 2.52 percent as strategic review advanced
Published on 10/04/2026 at 21:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNEXGEL stock (ISIN US65344E1073) was last at USD 0.17 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 2.52 percent on the session. The central corporate development is a strategic review and proposed platform reorganization introduced on September 24, 2026, according to the SEC.
Strategic review sets the direction
The filing says NEXGEL began using a shareholder update presentation titled Strategic Review & Proposed Platform Reorganization on September 24, 2026. The presentation was furnished under Regulation FD and outlines a review of operations, assets, liquidity and longer-term strategic direction.
The corporate move follows a shareholder vote on September 23, 2026. According to Stock Titan, investors approved an increase in authorized common shares from 25 million to up to 150 million and authorized a discretionary reverse split between 1-for-2 and 1-for-20.
Revenue growth meets a heavy loss
NEXGEL reported USD 3.69 million of revenue for the quarter ended June 30, 2026, compared with USD 2.88 million in the year-earlier quarter. The same report showed a GAAP net loss of USD 3.64 million, versus a GAAP net loss of USD 665,000 a year earlier, according to Markets Insider.
The latest quarterly figures therefore show a clear split between sales expansion and bottom-line pressure. The strategic review matters because the company is evaluating its asset portfolio and liquidity while the business absorbs its broader platform ambitions.
One analyst keeps a Hold view
Maxim Group analyst Naz Rahman maintained a Hold rating on September 25, 2026, as reported by Markets Insider. Investing.com lists a Neutral consensus based on one analyst, with zero Buy ratings, zero Sell ratings and one Hold rating, according to Investing.com.
For investors, the key tension is visible in the numbers: quarterly revenue reached USD 3.69 million, while the GAAP loss reached USD 3.64 million. The authorized-share decision and reverse-split authority also give the board additional capital-structure options during the review period.
NXGL remains near its yearly low
On October 2, 2026, NXGL traded at USD 0.17 on Nasdaq, with a 52-week range of USD 0.16 to USD 2.89. The session volume was 222,912 shares and market capitalization was USD 1.5 million as of the same date.
NEXGEL stock at a glance
- Company: NEXGEL, Inc.
- ISIN: US65344E1073
- Ticker: NXGL
- Trading venue: Nasdaq Capital Market
- Price as of October 2, 2026, 4:00 p.m. ET: USD 0.17
- Market capitalization: USD 1.5 million (as of October 2, 2026)
- 52-week range: USD 0.16-2.89 (as of October 2, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
